
Verrica Pharmaceuticals Inc.
VRCANasdaqCIK 1660334HealthcareFiscal year ends Dec 31
Reports and events: 160 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2024-05-1308:01 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-058208 |
| 2024-05-1307:46 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-136715 |
| 2024-04-1907:30 ET | DEF 14A | Proxy statementPeriod 2024-06-06 | 0001193125-24-101650 |
| 2024-02-2908:05 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-022659 |
| 2024-02-2907:45 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-051876 |
| 2024-01-0808:01 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-003926 |
| 2023-11-0907:54 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-061543 |
| 2023-11-0907:41 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-23-274069 |
| 2023-08-0807:52 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-039375 |
| 2023-08-0807:40 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-23-205590 |
| 2023-07-2716:15 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-23-196112 |
| 2023-07-2616:21 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-23-194625 |
| 2023-07-2407:31 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-191859 |
| 2023-06-0816:15 ET | 8-K | 5.07 Shareholder vote results | 0001193125-23-163516 |
| 2023-05-0908:27 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000950170-23-019169 |
| 2023-05-0908:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-23-138946 |
| 2023-04-2108:50 ET | DEF 14A | Proxy statementPeriod 2023-06-08 | 0001193125-23-109424 |
| 2023-03-0608:01 ET | 10-K | Annual reportPeriod 2022-12-31 | 0000950170-23-006118 |
| 2023-03-0607:46 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-23-060702 |
| 2023-02-2108:58 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-043040 |
| 2023-02-2106:08 ET | 8-K | 2.02 Results of operations; 8.01 Other events | 0001193125-23-042756 |
| 2023-02-0216:16 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-23-022755 |
| 2023-01-2407:58 ET | 8-K | 8.01 Other events | 0001193125-23-013704 |
| 2022-11-0716:30 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0000950170-22-022647 |
| 2022-11-0716:20 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-22-279108 |
| 2022-09-1408:09 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-22-244283 |
| 2022-08-1108:05 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0000950170-22-016660 |
| 2022-08-1107:50 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-22-218004 |
| 2022-07-1516:15 ET | SC 13D | Ownership report, active investor | 0001104659-22-080215 |
| 2022-07-1316:16 ET | 8-K | 8.01 Other events | 0001193125-22-192901 |
| 2022-07-0108:30 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-186748 |
| 2022-06-1416:31 ET | 8-K | 5.07 Shareholder vote results | 0001193125-22-173863 |
| 2022-06-0316:16 ET | 8-K | 2.05 Exit or disposal costs | 0001193125-22-167332 |
| 2022-05-2507:30 ET | 8-K | 8.01 Other events | 0001193125-22-159075 |
| 2022-05-0907:55 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0000950170-22-008242 |
| 2022-05-0907:38 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-22-144294 |
| 2022-04-2216:06 ET | DEF 14A | Proxy statementPeriod 2022-06-09 | 0001193125-22-115092 |
| 2022-04-0716:17 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-22-098900 |
| 2022-03-0216:56 ET | 10-K | Annual reportPeriod 2021-12-31 | 0000950170-22-002685 |
| 2022-03-0216:25 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-22-063013 |
| 2021-12-1516:26 ET | 8-K | 8.01 Other events | 0001193125-21-357955 |
| 2021-11-2917:07 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-21-342387 |
| 2021-11-1207:56 ET | 10-Q | Quarterly reportPeriod 2021-09-30 | 0000950170-21-004249 |
| 2021-11-1207:41 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-21-327358 |
| 2021-09-2916:06 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-21-286746 |
| 2021-09-2016:28 ET | 8-K | 8.01 Other events | 0001193125-21-277323 |
| 2021-08-1008:04 ET | 10-Q | Quarterly reportPeriod 2021-06-30 | 0001564590-21-042894 |
| 2021-08-1008:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-21-241222 |
| 2021-07-0908:28 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-21-211337 |
| 2021-06-1016:39 ET | 8-K | 5.07 Shareholder vote results | 0001193125-21-187840 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 14, 2026, 20:18 ET. Listed shows no prices and gives no investment advice.